What is ImmunityBio?
ImmunityBio is a vertically-integrated biotechnology company dedicated to creating advanced therapies and vaccines designed to enhance the body's natural immune response against cancers and infectious diseases. The company's core strategy involves leveraging its immunotherapy and cell therapy platforms, individually and in combination, to stimulate and sustain an immune response aimed at achieving durable and safe protection. A key development for ImmunityBio is ANKTIVA, its FDA-approved immunotherapy for non-muscle invasive bladder cancer with CIS, which activates natural killer cells, T cells, and memory T cells to promote long-duration responses. The company is also exploring potential cancer vaccines and other immunotherapies and cell therapies that could significantly reduce or eliminate the need for conventional high-dose chemotherapy, offering potentially more effective, accessible, and easily administered treatments in oncology and infectious diseases.
How much funding has ImmunityBio raised?
ImmunityBio has raised a total of $1.2B across 7 funding rounds:
Other Financing Round
$470M
Debt
$157M
Private Equity
$50M
Share Placement
$40M
Other Financing Round
$320M
Share Placement
$75M
Other Financing Round
$75M
Other Financing Round (2021): $470M with participation from Dr. Patrick Soon-Shiong and NantCapital
Debt (2022): $157M, investors not publicly disclosed
Private Equity (2023): $50M, investors not publicly disclosed
Share Placement (2023): $40M, investors not publicly disclosed
Other Financing Round (2024): $320M backed by Oberland Capital
Share Placement (2025): $75M, investors not publicly disclosed
Other Financing Round (2026): $75M led by Oberland Capital
Key Investors in ImmunityBio
Oberland Capital
Oberland Capital is a private investment firm focused on funding innovation in the global healthcare industry, managing approximately $3 billion in assets. The firm specializes in flexible investment structures tailored to meet the specific needs of its partners, offering a range of financing solutions including monetization of royalty streams and project-based financing.
Dr. Patrick Soon-Shiong
Dr. Patrick Soon-Shiong is a prominent figure in the biotechnology and healthcare sectors, known for his entrepreneurial ventures and contributions to medical innovation. His investment in ImmunityBio highlights a strategic alignment with the company's mission to develop novel immunotherapies.
NantCapital
NantCapital is an investment firm associated with Dr. Patrick Soon-Shiong, focusing on companies at the forefront of healthcare and biotechnology. Its backing of ImmunityBio signifies confidence in the company's scientific advancements and therapeutic potential.
What's next for ImmunityBio?
With the recent infusion of $75M in a major strategic investment, ImmunityBio is poised to accelerate the development and commercialization of its promising pipeline. The company's focus on activating the immune system to fight complex diseases, including its FDA-approved ANKTIVA for bladder cancer, positions it for significant growth. Future endeavors will likely concentrate on expanding the application of its platforms to a broader range of cancers and infectious diseases, potentially through further strategic partnerships and capital raises. The company's commitment to developing therapies that offer improved efficacy and reduced side effects aligns with evolving healthcare needs, suggesting a trajectory towards becoming a leader in the immunotherapy space.
See full ImmunityBio company page
